91 related articles for article (PubMed ID: 30726248)
1. Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin.
Agudelo M; Rodriguez CA; Zuluaga AF; Vesga O
PLoS One; 2019; 14(2):e0211096. PubMed ID: 30726248
[TBL] [Abstract][Full Text] [Related]
2.
Powles MA; Galgoci A; Misura A; Colwell L; Dingley KH; Tang W; Wu J; Blizzard T; Motyl M; Young K
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866878
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial.
Bradley JS; Makieieva N; Tøndel C; Roilides E; Kelly MS; Patel M; Vaddady P; Maniar A; Zhang Y; Paschke A; Chen LF
J Clin Pharmacol; 2023 Dec; 63(12):1387-1397. PubMed ID: 37562063
[TBL] [Abstract][Full Text] [Related]
4. Increased antibiofilm and growth inhibitory effect of Imipenem/Cilastatin nanoliposomes against clinical Pseudomonas aeruginosa isolates.
Milani F; Adibkia K; Hamishehkar H; Gholikhani T; Bani F; Milani M
J Mater Sci Mater Med; 2023 Sep; 34(10):47. PubMed ID: 37735291
[TBL] [Abstract][Full Text] [Related]
5. Corrigendum to "Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients" [Journal of Global Antimicrobial Resistance 36 (2024) 252-259].
You X; Dai Q; Hu J; Yu M; Wang X; Weng B; Cheng L; Sun F
J Glob Antimicrob Resist; 2024 Mar; 36():494. PubMed ID: 38521551
[No Abstract] [Full Text] [Related]
6. Tolerability of Meropenem and Ertapenem in a Patient with Documented Delayed Hypersensitivity Reaction to Imipenem-Cilastatin: A Literature Review.
Laajimi R; Mansour K; Chadli Z; Ben Fredj N; Ben Romdhane H; Chaabane A; Aouam K
Dermatitis; 2024 Apr; ():. PubMed ID: 38634839
[No Abstract] [Full Text] [Related]
7. Comparison of In Vivo Pharmacokinetics and Pharmacodynamics of Vancomycin Products Available in Korea.
Kim HK; Choi SM; Kang G; Park KH; Lee DG; Park WB; Rhee SJ; Lee S; Jung SI; Jang HC
Yonsei Med J; 2020 Apr; 61(4):301-309. PubMed ID: 32233172
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro antimicrobial potency, stability, colouration and dissolution time of generics versus innovator of meropenem in Europe.
Delattre IK; Briquet C; Wallemacq P; Tulkens PM; Van Bambeke F
Int J Antimicrob Agents; 2020 Jan; 55(1):105825. PubMed ID: 31634551
[TBL] [Abstract][Full Text] [Related]
9. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Review on Antimicrobial Pharmacokinetic Differences between Asian and Non-Asian Adult Populations.
Setiawan E; Cotta MO; Roberts JA; Abdul-Aziz MH
Antibiotics (Basel); 2023 Apr; 12(5):. PubMed ID: 37237706
[TBL] [Abstract][Full Text] [Related]
11. Comparative review of imipenem/cilastatin versus meropenem.
Salmon-Rousseau A; Martins C; Blot M; Buisson M; Mahy S; Chavanet P; Piroth L
Med Mal Infect; 2020 Jun; 50(4):316-322. PubMed ID: 32035719
[TBL] [Abstract][Full Text] [Related]
12. Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients.
Barbier F; Hraiech S; Kernéis S; Veluppillai N; Pajot O; Poissy J; Roux D; Zahar JR;
Ann Intensive Care; 2023 Jul; 13(1):65. PubMed ID: 37462830
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the Use of Beta-Lactam Antibiotics in Clinical Practice: A Test of Time.
Tilanus A; Drusano G
Open Forum Infect Dis; 2023 Jul; 10(7):ofad305. PubMed ID: 37416756
[TBL] [Abstract][Full Text] [Related]
14. The place of new antibiotics for Gram-negative bacterial infections in intensive care: report of a consensus conference.
Dequin PF; Aubron C; Faure H; Garot D; Guillot M; Hamzaoui O; Lemiale V; Maizel J; Mootien JY; Osman D; Simon M; Thille AW; Vinsonneau C; Kuteifan K
Ann Intensive Care; 2023 Jul; 13(1):59. PubMed ID: 37400647
[TBL] [Abstract][Full Text] [Related]
15. Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review.
Venuti F; Trunfio M; Martson AG; Lipani F; Audagnotto S; Di Perri G; Calcagno A
Drugs; 2023 Jul; 83(11):967-983. PubMed ID: 37314633
[TBL] [Abstract][Full Text] [Related]
16. Meropenem Model-Informed Precision Dosing in the Treatment of Critically Ill Patients: Can We Use It?
Li L; Sassen SDT; Ewoldt TMJ; Abdulla A; Hunfeld NGM; Muller AE; de Winter BCM; Endeman H; Koch BCP
Antibiotics (Basel); 2023 Feb; 12(2):. PubMed ID: 36830294
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid concentrations of fluoroquinolones and carbapenems in tuberculosis meningitis.
Maranchick NF; Alshaer MH; Smith AGC; Avaliani T; Gujabidze M; Bakuradze T; Sabanadze S; Avaliani Z; Kipiani M; Peloquin CA; Kempker RR
Front Pharmacol; 2022; 13():1048653. PubMed ID: 36578553
[No Abstract] [Full Text] [Related]
18. Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study.
Kumta N; Heffernan AJ; Cotta MO; Wallis SC; Livermore A; Starr T; Wong WT; Joynt GM; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0014222. PubMed ID: 35862757
[TBL] [Abstract][Full Text] [Related]
19. Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.
Heo YA
Drugs; 2021 Feb; 81(3):377-388. PubMed ID: 33630278
[TBL] [Abstract][Full Text] [Related]
20. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.
Mansour H; Ouweini AEL; Chahine EB; Karaoui LR
Am J Health Syst Pharm; 2021 Mar; 78(8):674-683. PubMed ID: 33580649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
